IMRIS

IMRIS founded in 2005, IMRIS is a global provider of intraoperative imaging solutions.
The company's flagship product is The IMRIS Surgical Theatre. A hybrid operating theatre with intraoperative imaging capabilities, The IMRIS Surgical Theatre incorporates design and technology provided by IMRIS, including the moveable intraoperative MRI, as well as technology from 3rd-party medical device companies. IMRIS designs, creates and supports The IMRIS Surgical Theatre, which the company's marketing materials describe as "the world’s most advanced hybrid operating theatre."
History.
In 2005, IMRIS evolved from research related to intraoperative imaging conducted through Canada's National Research Council.
In 2011, the company announced it was developing an MRI-compatible image-guided surgical robot specifically designed for minimally invasive neurosurgery. In November 2012, the company announced that it was moving its headquarters to the Minneapolis area. They completed their move in July 2013.
In late May 2015, news broke that IMRIS had "filed for chapter 11 bankruptcy protection with a buyout offer of $9.5 million from secured lender Deerfield Management Co. LP." due to problems competing with larger health care businesses. Chapter 11 proceedings were finalized on August 19, 2015, with Deerfield Imaging agreeing to acquire most of IMRIS' assets.
In 2017, the company marked its two-year anniversary under new ownership, reporting strong financial growth and strategic investments. With the support of parent company Deerfield Management in August 2015, IMRIS emerged under a new LLC, brand, leadership and focus. Since then, IMRIS achieved record earnings before interest, taxes, depreciation and amortization (EBITDA) generation, 44 percent revenue growth in 2016, as well as 68 percent growth in 2017 year-to-date (YTD) contract bookings through contracts with top-tier hospitals around the world. In addition, IMRIS continues to add a significant number of new employees to support current business and expected growth.